Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Weinstein

Interventional Cardiology Memphis, TN Medical Doctor

NPI 1922003037 CMS profile 87250

4901 Raleigh Common Drive, Suite 100, Memphis, TN 38128

Open in the dashboard

General payments

$218,322

691 records reported · program years 2019–2025

Research payments

$92,800

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$434,879 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Joseph Weinstein of Memphis, TN is reported in the CMS Open Payments database as having received $218,322 across 691 general payments and $92,800 in research payments paid to them. Separately, studies naming them as principal investigator received $434,879 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,165 41
2024 General $7,057 55
2024 Research $92,800 2
2023 General $13,790 91
2022 General $53,686 128
2021 General $15,219 87
2020 General $9,821 113
2019 General $117,583 176

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Weinstein
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Joseph Weinstein were reported at $1,165. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Joseph Weinstein Interventional Cardiology median Middle half National median
2019 $117,583 $1,097 $329–$3,048 $163
2020 $9,821 $473 $161–$1,480 $114
2021 $15,219 $677 $233–$1,827 $132
2022 $53,686 $978 $333–$2,724 $149
2023 $13,790 $1,136 $382–$2,986 $160
2024 $7,057 $1,181 $395–$3,326 $164
2025 $1,165 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $199,792 277 payments
  2. Medtronic Vascular, Inc. $2,998 42 payments
  3. Biotronik Inc. $1,728 8 payments
  4. Esperion Therapeutics, Inc. $1,694 5 payments
  5. Abiomed $1,295 16 payments
  6. Abbott Laboratories $1,216 34 payments
  7. Amgen Inc. $919 50 payments
  8. Boston Scientific Corporation $888 11 payments
  9. Novartis Pharmaceuticals Corporation $783 45 payments
  10. Medtronic, Inc. $708 9 payments
  11. Other $6,301 194 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $163,575 58 payments
  2. Travel and Lodging $34,313 75 payments
  3. Food and Beverage $19,836 552 payments
  4. Consulting Fee $425 2 payments
  5. Education $173 4 payments
Products named General payments · program years 2019–2025
  1. XARELTO $199,888 277 payments
  2. Resolute $2,552 37 payments
  3. NEXLETOL $1,694 5 payments
  4. NEXLIZET $1,620 1 payment
  5. Impella $1,221 15 payments
  6. Repatha $825 45 payments
  7. ENTRESTO $506 29 payments
  8. LifeVest $505 16 payments
  9. VERQUVO $482 23 payments
  10. JARDIANCE $387 20 payments
  11. Other $9,148 253 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $92,800 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

7,295

Median for Cardiology: 2,533

Drug cost

$1,328,908

Median for Cardiology: $485,213

Branded share of claims

29.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 563 $473,226
Repatha Sureclick Evolocumab Brand 272 $190,213
Entresto Sacubitril/Valsartan Brand 132 $136,596
Eliquis Apixaban Brand 123 $109,089
Jardiance Empagliflozin Brand 65 $58,483
Farxiga Dapagliflozin Propanediol Brand 50 $42,242
Ozempic Semaglutide Brand 41 $40,893
Praluent Pen Alirocumab Brand 68 $40,093
Multaq Dronedarone Hcl Brand 33 $37,158
Brilinta Ticagrelor Brand 59 $36,112

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$762,003

Of which drugs: $6,456

Medicare patients

881

Average age 75

Services billed

15,552

423 women, 458 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 48%
Diabetes 39%
Atrial fibrillation 27%
Chronic kidney disease 27%
Heart failure 20%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 332 1,278 $6,456

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $5,789
$5,789 563 —
VERQUVO
  • Merck Sharp & Dohme Corporation $74
$74 — —
ELIQUIS
  • PFIZER INC. $37
  • E.R. Squibb & Sons, L.L.C. $33
$71 123 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $59
$59 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

693 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record